2025.02.12 -

Caliway Biopharmaceuticals Added to MSCI World Small Cap Index, Reinforcing Global Standing

Caliway has been added to the MSCI World Small Cap Index, as announced today by MSCI (Morgan Stanley Capital International) in its latest quarterly review.

2025.02.09 -

Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints

Caliway announced today that CBL-514’s second Phase 2b clinical study (CBL-0205) successfully met its primary and all critical secondary efficacy endpoints.

2025.02.03 -

Caliway Presented CBL-0204 Phase 2b Study Results of CBL-514 at IMCAS 2025 in Paris

Innovative Non-Surgical Fat Reduction Treatment Gains International Attention

2024.12.19 -

Caliway to Present CBL-514 Phase 2b Study Results for Subcutaneous Fat Reduction at IMCAS 2025 in Paris

The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction therapies and further detailed in the Non-surgical Body Contouring session through an oral presentation.

2024.12.11 -

Caliway Announces Successful Study Results from CBL-0204, a CBL-514 Phase 2b Study for Reducing Abdominal Subcutaneous Fat, Met All Primary and Secondary Efficacy Endpoints

CBL-514 Phase 2b study for subcutaneous fat reduction (CBL-0204 Phase 2b study) met all the primary and secondary efficacy endpoints in the FAS (Full analysis set) and PP (Per-protocol) population analysis.

Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices

Caliway is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index.

2024.11.12 -

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum’s Disease Treatment

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum’s disease treatment.

2024.10.23 -

Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction

The first and only lipolytic injectable for large area – CBL-514’s last Phase 2b study has been completed